Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth

Pediatric Infectious Disease Journal

Volumn 33, Issue 5, 2014, Pages 511-517

  Wood, Nicholas ^a,b,c   Marshall, Helen ^d,e   White, Olivia J ^f,g   Holt, Patrick G ^f,g   McIntyre, Peter ^a,b  

^a NATIONAL CENTRE FOR IMMUNISATION RESEARCH AND SURVEILLANCE   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

acellular pertussis vaccine; birth; immunogenicity

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; GAMMA INTERFERON; HEMAGGLUTININ; INTERLEUKIN 13; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; MEASLES MUMPS RUBELLA VACCINE; PERTACTIN; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; PREVENAR 7; TETANUS ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADHESIN; BACTERIUM ANTIBODY; BORDETELLA VIRULENCE FACTOR; DIPHTHERIA TOXIN; FILAMENTOUS HEMAGGLUTININ ADHESIN, BORDETELLA PERTUSSIS; IMMUNOGLOBULIN G; OUTER MEMBRANE PROTEIN; PERTUSSIS TOXOID; TETANUS TOXIN; TOXOID;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHILD; CYTOKINE RESPONSE; DIPHTHERIA; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MEASLES; MUMPS; PERTUSSIS; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RUBELLA; TETANUS; BLOOD; FEMALE; IMMUNOLOGY; INFANT; MALE; NEWBORN; TIME;

ADHESINS, BACTERIAL; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CHILD, PRESCHOOL; DIPHTHERIA TOXIN; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MALE; PERTUSSIS VACCINE; TETANUS TOXIN; TIME FACTORS; TOXOIDS; VIRULENCE FACTORS, BORDETELLA;

EID: 84899492207     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000246     Document Type: Article

References (22)

1. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Vaccine preventable diseases and vaccination coverage in Australia, 2003-2005. Commun Dis Intell 2007;31:S1-S152.
2. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J. 2005;24(5 suppl):S10-S18.
3. Tanaka M, Vitek C, Pascual F et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003; 23: 2968-2975.
4. Wood N, Siegrist CA. Neonatal immunization: where do we stand? Curr Opin Infect Dis. 2011;24:190-195.
5. McIntyre P, Wood N. Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect Dis. 2009;22:215-223.
6. Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a threecomponent acellular pertussis vaccine administered at birth. Pediatrics. 2003;111(5 Pt 1):1042-1045.
7. Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr. 2008;152:655-660, 660.e1.
8. Wood N, McIntyre P, Marshall H, et al. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J. 2010;29:209-215.
9. Halasa NB, O'Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr. 2008;153: 327-332.
10. Baraff LJ, Leake RD, Burstyn DG, et al. Immunologic response to early and routine DTP immunization in infants. Pediatrics. 1984;73:37-42.
11. Provenzano RW, Wetterlow LH, Sullivan CL. Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth. N Engl J Med. 1965;273:959-965.
12. Siegrist CA. Blame vaccine interference, not neonatal immunization, for suboptimal responses after neonatal diphtheria, tetanus, and acellular pertussis immunization. J Pediatr. 2008;153:305-307.
13. Knuf M, Schmitt HJ, Jacquet JM, et al. Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr. 2010;156:675-678.
14. White OJ, Rowe J, Richmond P, et al. Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine. 2010;28:2648-2652.
15. White OJ, McKenna KL, Bosco A, et al. A genomics-based approach to assessment of vaccine safety and immunogenicity in children. Vaccine. 2012;30:1865-1874.
16. Hallander HO, Gustafsson L, Ljungman M, et al. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 -6 years after the third vaccine dose. Vaccine. 2005;23:5359-5364.
17. Hallander HO, Ljungman M, Storsaeter J, et al. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS. 2009;117:797-807.
18. Storsaeter J, Hallander HO, Gustafsson L, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16:1907-1916.
19. Olin P, Hallander HO, Gustafsson L, et al. How to make sense of pertussis immunogenicity data. Clin Infect Dis. 2001;33 (suppl 4):S288-S291.
20. Tichmann I, Grunert D, Habash S, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin. 2006;2:249-254.
21. Pichichero M, Edwards K, Anderson E, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four to six year old children. Pediatrics 2000;105:1-8
22. Rowe J, Yerkovich ST, Richmond P, et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4-to 6-year-old children. Infect Immun. 2005;73:8130-8135.